Engineered anti-il-23 antibodies
AssigneeSchering Corporation
InventorsLeonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
Life of this patent
Estimating the term…
Abstract
Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
Claims19
1-32. (canceled)
An antibody, or antigen binding fragment thereof, that binds to human IL-23 (SEQ ID NO:
- 29), said antibody or antigen binding fragment comprising:
- a) a CDR-L1 sequence consisting of residues 43-53 of SEQ ID NO:
- 2;
- b) a CDR-L2 sequence consisting of residues 69-75 of SEQ ID NO:
- 2;
- c) a CDR-L3 sequence consisting of residues 108-116 of SEQ ID NO:
- 2;
- d) a CDR-H1 sequence consisting of residues 45-54 of SEQ ID NO:
- 1;
- e) a CDR-H2 sequence consisting of residues 69-85 of SEQ ID NO:
- 1;
- and
- f) a CDR-H3 sequence consisting of residues 118-123 of SEQ ID NO:
- 1.
An antibody, or antigen binding fragment thereof, that is able to block the binding of a second antibody to human IL-23p19 (SEQ ID NO:
- 29) in a cross-blocking assay, wherein the second antibody comprises:
- a) a light chain consisting of residues 20-233 of SEQ ID NO:
- 2;
- and
- b) a heavy chain consisting of residues 20-464 of SEQ ID NO:
- 1.
An antibody, or antigen binding fragment thereof, that binds to human IL-23 (SEQ ID NO:
- 29), said antibody or antigen binding fragment comprising:
- a) a CDR-L1 sequence consisting of residues 43-53 of SEQ ID NO:
- 4;
- b) a CDR-L2 sequence consisting of residues 69-75 of SEQ ID NO:
- 4;
- c) a CDR-L3 sequence consisting of residues 108-116 of SEQ ID NO:
- 4;
- d) a CDR-H1 sequence consisting of residues 45-54 of SEQ ID NO:
- 3;
- e) a CDR-H2 sequence consisting of residues 69-85 of SEQ ID NO:
- 3;
- and
- f) a CDR-H3 sequence consisting of residues 118-123 of SEQ ID NO:
- 3.
An antibody, or antigen binding fragment thereof, that is able to block the binding of a second antibody to human IL-23p19 (SEQ ID NO:
- 29) in a cross-blocking assay, wherein the second antibody comprises:
- a) a light chain consisting of residues 20-233 of SEQ ID NO:
- 4;
- and
- b) a heavy chain consisting of residues 20-464 of SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.